MYC-Targeting PROTACs Lead to Bimodal Degradation and N-Terminal Truncation
ACS Chemical Biology · 2025-04-18 · 20 (4) · 896-906
DOI: 10.1021/acschembio.4c00864 ↗At a glance
Journal article in ACS Chemical Biology, published online on 2025-03-27. Written by Shelton R Boyd and 8 co-authors. Institution: Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, Uni…. Major MEDLINE topics: Proteolysis, Proto-Oncogene Proteins c-myc, Antineoplastic Agents, Small Molecule Libraries. Cited 23 times so far (Crossref); 49 references. Funded by: Baylor College of Medicine, Bill and Melinda Gates Foundation, Adrienne Helis Malvin Medical Research Foundation.
Abstract (original language)
MYC is a master regulatory transcription factor whose sustained dysregulation promotes the initiation and maintenance of numerous cancers. While MYC is a regarded as a potenial therapeutic target in cancer, its intrinsically disordered structure has proven to be a formidable barrier toward the development of highly effective small molecule inhibitors. We rationalized that proteolysis targeting chimeras (PROTACs), which might accomplish the targeted degradation of MYC, would achieve more potent cell killing in MYC-driven cancer cells than reversible inhibitors. PROTACs are bifunctional small molecules designed to produce a ternary complex between a target protein and an E3 ligase leading the target's ubiquitination and degradation by the 26S proteasome. We generated PROTAC MTP3 based on modifications of the previously reported MYC-targeting compound KJ-Pyr-9. We found that MTP3 depletes endogenous full-length MYC proteins and uniquely induces increasing levels of a functional, N-terminally truncated MYC species, tMYC. Furthermore, MTP3 perturbs cellular MYC levels in favor of a tMYC-dominated state whose gene regulatory landscape is not significantly altered compared to that of wild type MYC. Moreover, although it lacks ∼10 kDa of MYC's N-terminal transactivation domain, tMYC is sufficient to maintain an oncogenic proliferative state. Our results highlight the complexities of proximity-inducing compounds against highly regulated and conformationally dynamic protein targets such as MYC and indicate that PROTACs can induce alternative outcomes beyond target protein degradation.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Verna and Marrs McLean Department of Biochemistry and Molecular Pharmacology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, United States.
- Center for Drug Discovery, Department of Pathology and Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, United States.
- Department of Pediatrics─Neurology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, United States.
- Jan and Dan Duncan Neurological Research Institute, Texas Children's Hospital, Houston, Texas 77030, United States.
ORCID profiles: Shelton R Boyd, Srinivas Chamakuri, Hu Chen, Antrix Jian, Jian Wang, Damian W Young
Funding
- Baylor College of Medicine
- Bill and Melinda Gates Foundation
- Adrienne Helis Malvin Medical Research Foundation
- Cancer Prevention and Research Institute of Texas
Cite
APA
Boyd, S. R., Chamakuri, S., Trostle, A. J., Chen, H., Liu, Z., Jian, A., Wang, J., Malovannaya, A., & Young, D. W. (2025). MYC-Targeting PROTACs Lead to Bimodal Degradation and N-Terminal Truncation. ACS Chemical Biology, 20(4), 896-906. https://doi.org/10.1021/acschembio.4c00864
Vancouver
Boyd SR, Chamakuri S, Trostle AJ, Chen H, Liu Z, Jian A, et al. MYC-Targeting PROTACs Lead to Bimodal Degradation and N-Terminal Truncation. ACS Chemical Biology. 2025;20(4):896-906. doi:10.1021/acschembio.4c00864
BibTeX
@article{Boyd2025,
author = {Boyd, Shelton R and Chamakuri, Srinivas and Trostle, Alexander J and Chen, Hu and Liu, Zhandong and Jian, Antrix and Wang, Jian and Malovannaya, Anna and Young, Damian W},
title = {MYC-Targeting PROTACs Lead to Bimodal Degradation and N-Terminal Truncation},
journal = {ACS Chemical Biology},
year = {2025},
volume = {20},
number = {4},
pages = {896--906},
doi = {10.1021/acschembio.4c00864}
}
EUVIMED